Guido PC, Perez M, Halac A, et al. - In patients with pediatric cystic fibrosis (CF), researchers developed a population pharmacokinetic (PopPK) model characterizing amikacin [commonly used in pediatric CF patients for the treatment of pulmonary exacerbations] disposition. Participants in the study were 39 patients (114 amikacin concentrations) with CF under 18 years of age with pulmonary exacerbation who received amikacin. Depending on the patient's status and hospital protocols, patients received different amikacin regimens (30 mg⁻¹ kg⁻¹ day⁻¹ every 8, 12, or 24 hours). For therapeutic drug monitoring, amikacin serum levels were obtained. Using MONOLIX Suite-2018R1 (Lixoft), PopPK model was developed. Findings suggested that the 30 mg⁻¹ kg⁻¹ day⁻¹ regimen every 24 hours more appropriately met the therapeutic target for amikacin. While all patients had good clinical outcomes and a good profile of adverse events, further studies are needed to redefine the optimal treatment strategy.